<SEC-DOCUMENT>0001493152-25-001559.txt : 20250110
<SEC-HEADER>0001493152-25-001559.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110074511
ACCESSION NUMBER:		0001493152-25-001559
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250107
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		25520454

	BUSINESS ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:MBOT="http://MICROBOTMEDICAL.com/20250107">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_MBOT_MICROBOTMEDICAL.com_20250107 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20250107_20250107 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000883975 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000004" name="dei:EntityCentralIndexKey">0000883975</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mbot-20250107.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-01-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-07</xbrli:startDate>
        <xbrli:endDate>2025-01-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20250107__20250107_zno50pUQdTlh"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_903_edei--DocumentPeriodEndDate_c20250107__20250107_zgdwzJ1AlWsd"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">January 7, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20250107__20250107_zuJ0OI8RMfMc"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000011" name="dei:EntityRegistrantName">MICROBOT
MEDICAL INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20250107__20250107_zx2is3eHecu3"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20250107__20250107_zGva8GuoKy3j"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000013" name="dei:EntityFileNumber">000-19871</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20250107__20250107_z6G1z1lmXfF6"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000014" name="dei:EntityTaxIdentificationNumber">94-3078125</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20250107__20250107_zyZR5cHAWGSg"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000015" name="dei:EntityAddressAddressLine1">288
Grove Street</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20250107__20250107_zYAWS9Cy6gKl"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 388</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20250107__20250107_zPC76qMga6Q"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000017" name="dei:EntityAddressCityOrTown">Braintree</ix:nonNumeric></span>,
<span id="xdx_903_edei--EntityAddressStateOrProvince_c20250107__20250107_zKiVfU4anS7k"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20250107__20250107_zwZtPs6NcPy3"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000019" name="dei:EntityAddressPostalZipCode">02184</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of Principal Executive Offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_90A_edei--CityAreaCode_c20250107__20250107_zdkjvBCKDcGf"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000020" name="dei:CityAreaCode">(781)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20250107__20250107_zvYGfZBPWMp2"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000021" name="dei:LocalPhoneNumber">875-3605</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
Name or Former Address, if Changed Since Last Report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--WrittenCommunications_c20250107__20250107_z6Jm0hSSMs86"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SolicitingMaterial_c20250107__20250107_zNDKUW0TPqXl"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250107__20250107_zMHMW6PFM6jb"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20250107__20250107_zjybkx8Uhs1k"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    registered pursuant to Section 12(b) of the Act:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20250107__20250107_zMopyiQjlIQf"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20250107__20250107_zUDwkPIdEX0j"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000027" name="dei:TradingSymbol">MBOT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_90E_edei--SecurityExchangeName_c20250107__20250107_zHvekctv4kr1"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>
    Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250107__20250107_z9Kg4flkeLQk"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01. Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2025, Microbot Medical Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into Securities Purchase Agreements
(the &#8220;Purchase Agreements&#8221;) with investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and
sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the &#8220;Registered Offering&#8221;),
an aggregate of 3,788,550 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (&#8220;Common
Stock&#8221;), at an offering price of $2.27 per share, for aggregate gross proceeds from the Offerings (as defined below) of approximately
$8.6 million before deducting the placement agent fee (as described in greater detail below) and related offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
Purchase Agreements contain customary representations and warranties and agreements of the Company and the Investors and customary indemnification
rights and obligations of the parties. Pursuant to the terms of each of the Purchase Agreements, the Company has agreed to certain restrictions
on the issuance and sale of its Common Stock or Common Stock Equivalents (as defined in the Purchase Agreements) during the 30-day period
following the closing of the Registered Offering.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-275634), which was filed with the Securities
and Exchange Commission (the &#8220;Commission&#8221;) on November 17, 2023, amended on November 30, 2023 and was declared effective
by the Commission on December 4, 2023 (the &#8220;Registration Statement&#8221;), a base prospectus dated December 4, 2023 and a prospectus
supplement dated January 7, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement (the &#8220;Private Placement&#8221; and, together with the Registered Offering, the &#8220;Offerings&#8221;),
the Company agreed to issue to the Investors Series H preferred investment options to purchase up to 7,577,100 shares of Common Stock
(the &#8220;Series H Warrants&#8221;) at an exercise price of $2.10 per share. Each Series H Warrant is exercisable immediately and will
expire two years from the initial exercise date. The Series H Warrants and the shares of the Common Stock issuable upon the exercise
of the Series H Warrants (the &#8220;Series H Warrant Shares&#8221;) are not being registered under the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), were not offered pursuant to the Registration Statement and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act, and Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offerings are expected to close on or about January 10, 2025, subject to the satisfaction of customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder (together with its affiliates) may not exercise any portion of the Series H Warrants to the extent that the holder would own more
than 4.99% (or, at the purchaser&#8217;s option upon issuance, 9.99%) of the Company&#8217;s outstanding Common Stock immediately after
exercise. However, upon at least 61 days&#8217; prior notice from the holder to the Company, a holder with a 4.99% ownership blocker
may increase the amount of ownership of outstanding Common Stock after exercising the holder&#8217;s Series H Warrants up to 9.99% of
the number of the Company&#8217;s Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is determined in accordance with the terms of the Series H Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 29, 2024, the Company entered into an engagement letter, as amended on January 3, 2025, in connection with the Offerings (as amended,
the &#8220;Engagement Letter&#8221;), with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;), pursuant to which Wainwright agreed
to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.
As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the
gross proceeds received by the Company from the Offerings, plus a management fee equal to 1.0% of the gross proceeds received by the
Company from the Offerings, a non-accountable expense of $25,000, up to $35,000 for its fees and expenses of legal counsel and $15,950
for clearing expenses. The Company has also agreed to issue to Wainwright or its designees warrants to purchase 189,428 shares of Common
Stock (the &#8220;Wainwright Warrants&#8221; and, together with the Series H Warrants, the &#8220;Warrants&#8221;). The Wainwright Warrants
are exercisable immediately, will expire two years from issuance, and have an exercise price of $2.8375 per share. Further, pursuant
to the Engagement Letter, Wainwright is entitled to compensation with respect to any financing of the Company occurring within six months
of the termination of the Engagement Letter when such financing is provided by investors whom Wainwright introduced to the Company during
the term of the Engagement Letter. Further, pursuant to the Engagement Letter, Wainwright has a right of first refusal to act as sole
book-running manager, sole underwriter or sole placement agent with respect to any public offering or private placement of equity, equity-linked
or debt securities using an underwriter or placement agent occurring during the twelve-month period following the termination of the
Engagement Letter. In addition, upon any exercise for cash of any Series H Warrants issued to investors in the Offering, the Company
shall pay Wainwright, within five (5) business days of the Company&#8217;s receipt of the exercise price, a cash fee of seven (7.0%)
percent of the aggregate gross exercise price paid in cash with respect thereto. Also, upon any exercise for cash of any Series H Warrants
issued to investors in the Offering, the Company shall issue to Wainwright (or its designees), within five (5) business days of the Company&#8217;s
receipt of the exercise price, warrants to purchase that number of shares of Common Stock of the Company equal to five (5.0%) percent
of the aggregate number of such shares of Common Stock underlying the preferred investment options that have been so exercised. The Engagement
Letter also includes indemnification obligations of the Company and other provisions customary for transactions of this nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
of the Wainwright Warrants nor the shares of Common Stock issuable upon the exercise of the Wainwright Warrants (the &#8220;Wainwright
Warrant Shares&#8221;) are registered under the Securities Act. The Wainwright Warrants and the Wainwright Warrant Shares were issued
in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock is listed on The Nasdaq Capital Market. There is no established trading market for the Warrants, and the Company does not
intend to list the Warrants on any securities exchange or nationally recognized trading system. Without a trading market, the liquidity
of the Warrants may be extremely limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summaries of the form of Series H Warrant, the form of Wainwright Warrant and the form of Purchase Agreement do not purport
to be complete and are subject to, and qualified in their entirety by, such documents attached as Exhibits 4.1, 4.2 and 10.1, respectively,
to this Current Report on Form 8-K, which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor
shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. relating to the legality of the issuance and sale of the Shares
is attached as Exhibit 5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02. Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 1.01 above related to the Warrants, the Series H Warrant Shares and the Wainwright Warrant Shares is incorporated
herein by reference into this Item 3.02.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01. Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2025, the Company issued a press release announcing the Offerings, a copy of which is attached hereto as Exhibit 99.1 and
is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Series H Warrant.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Form of Wainwright Warrant.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement, dated as of January 7, 2025, by and among the Company and the purchasers party thereto.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Pricing Press Release.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MICROBOT
    MEDICAL INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Harel Gadot</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    January 10, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5lppGC9JPi4pYRYqIv8GuEmyzZROrHslbGlvEZWFZZt6MECOxoqWpkeE0Lws4YNPW2iOUeEFGe8bgyNebDMIt8WqcZ219//7AnAKDgUljleog9NbOOKwykMlYzsYqBTnNJgr2WxF99ZzsxVRovdE1aFvBnqllg17za0g46CdZal591RHZGbIZJLEc5DcomSjYUacfxDcHRZGLaNRPJFZM9za4Fk+P9kvCosYm1LmB/m/0AQetSo4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
H PREFERRED INVESTMENT OPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Investment Option
Shares: ________ </FONT></TD><TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue Date: January __, 2025</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES H PREFERRED INVESTMENT OPTION (the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received, __________
or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior
to 5:00 p.m. (New York City time) on _____ (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase
from Microbot Medical Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to _____ shares (as subject to adjustment hereunder,
the &ldquo;<U>Preferred Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this
Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated January 7, 2025, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Preferred Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be
made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Preferred Investment Option Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified
in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. The Company shall have no obligation to inquire with respect
to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor the authority of the person so executing
such Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Preferred Investment Option to the Company until the Holder has purchased all of the Preferred Investment Option Shares available hereunder
and the Preferred Investment Option has been exercised in full, in which case, the Holder shall surrender this Preferred Investment Option
to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Preferred Investment Option resulting in purchases of a portion of the total number of Preferred Investment
Option Shares available hereunder shall have the effect of lowering the outstanding number of Preferred Investment Option Shares purchasable
hereunder in an amount equal to the applicable number of Preferred Investment Option Shares purchased. The Holder and the Company shall
maintain records showing the number of Preferred Investment Option Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Preferred Investment Option, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Preferred Investment Option Shares hereunder, the number of Preferred Investment Option Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$2.10</B>, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment
Option may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall
be entitled to receive a number of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
    Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
    and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined
    in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder,
    either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of
    the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of
    the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading
    hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of
    &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable
    Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
    pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Preferred Investment Option, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Preferred Investment Option Shares that would be issuable upon exercise of this Preferred Investment Option in accordance
    with the terms of this Preferred Investment Option if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the <FONT STYLE="background-color: white">Purchasers
</FONT>of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment
Options being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding
period of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery of Preferred Investment Option Shares Upon Exercise</U>.
The Company shall cause the Preferred Investment Option Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder
by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its
Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either
(A) there is an effective registration statement permitting the issuance of the Preferred Investment Option Shares to or resale of the
Preferred Investment Option Shares by the Holder or (B) the Preferred Investment Option Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Preferred Investment Options), and
otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee,
for the number of Preferred Investment Option Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company
of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company
of the Notice of Exercise (such date, the &ldquo;<U>Preferred Investment Option Share Delivery Date</U>&rdquo;). Upon delivery of the
Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Preferred Investment
Option Shares with respect to which this Preferred Investment Option has been exercised, irrespective of the date of delivery of the
Preferred Investment Option Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Preferred Investment Option
Shares subject to a Notice of Exercise by the Preferred Investment Option Share Delivery Date, the Company shall pay to the Holder, in
cash, as liquidated damages and not as a penalty, for each $1,000 of Preferred Investment Option Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the third Trading Day after the Preferred Investment Option Share Delivery Date) for each Trading Day after such Preferred Investment
Option Share Delivery Date until such Preferred Investment Option Shares are delivered or Holder rescinds such exercise. The Company
agrees to maintain a transfer agent that is a participant in the FAST program so long as this Preferred Investment Option remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part,
the Company shall, at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery
of the Preferred Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder
to purchase the unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred Investment
Option shall in all other respects be identical with this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares pursuant to Section 2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind
such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other
rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option
Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Preferred Investment Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then
the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including reasonable
and customary brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Preferred Investment Option Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Preferred Investment Option and equivalent number of Preferred Investment Option Shares for
which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares
of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For
example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an
attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause
(A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the
amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver shares of Common Stock upon exercise of the Preferred Investment Option as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Preferred Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any
issue or transfer tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which
taxes and expenses shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder
or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment
Option Shares are to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Preferred Investment Option, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder
shall not have the right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
(such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Preferred Investment
Option with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, nonexercised portion of this Preferred Investment Option beneficially owned by the Holder
or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or
exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that
the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in
this Section 2(e) applies, the determination of whether this Preferred Investment Option is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Preferred Investment Option is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Preferred Investment Option, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Preferred Investment Option. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Preferred Investment Option held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof)
which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately
adjusted such that the aggregate Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Preferred
Investment Option is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Preferred
Investment Option (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make
any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Preferred Investment Option, then, in each such case, the Holder shall be entitled to participate
in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than solely
for the purpose of changing the Company&rsquo;s name and/or the jurisdiction of incorporation of the Company or a holding company for
the Company), (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of more than 50% of the outstanding Common Stock or more than 50% of the voting power of the common equity of the Company, (iv) the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Preferred Investment Option, the Holder shall have the right to receive, for each Preferred
Investment Option Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option), the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Preferred Investment Option is exercisable immediately prior to such
Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Preferred Investment Option from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of
this Preferred Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental
Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall
only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid to the holders
of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock
or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or
paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of
the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the volatility for the remaining exercise period as obtained from the HVT function on Bloomberg (determined utilizing
a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the share price on the day of completion of the transaction (D)
a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other
consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
&ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Preferred Investment Option
and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and
substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Preferred Investment Option a security of the Successor
Entity evidenced by a written instrument substantially similar in form and substance to this Preferred Investment Option which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Preferred Investment Option (without regard to any limitations on the exercise
of this Preferred Investment Option) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price
hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such
Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price
being for the purpose of protecting the economic value of this Preferred Investment Option immediately prior to the consummation of such
Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental
Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Preferred Investment Option (so that from
and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Preferred Investment Option
and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the
Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume
all of the obligations of the Company prior thereto under this Preferred Investment Option and the other Transaction Documents with the
same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Preferred Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. The <FONT STYLE="background-color: white">Holder agrees to maintain any information
disclosed pursuant to this <U>Section 3(f)(ii)</U> in confidence until such information is publicly available, and shall comply with
applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Preferred Investment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Preferred Investment Option and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Preferred Investment Option
at the principal office of the Company or its designated agent, together with a written assignment of this Preferred Investment Option
substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer
taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Preferred Investment Option or Preferred Investment Options in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Preferred Investment
Option evidencing the portion of this Preferred Investment Option not so assigned, and this Preferred Investment Option shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Preferred
Investment Option to the Company unless the Holder has assigned this Preferred Investment Option in full, in which case, the Holder shall
surrender this Preferred Investment Option to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment
form to the Company assigning this Preferred Investment Option in full. The Preferred Investment Option, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Preferred Investment Option Shares without having a new Preferred Investment
Option issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Preferred Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment
Options upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Preferred Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred
Investment Option or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to
be divided or combined in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated
the Issue Date of this Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number
of Preferred Investment Option Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Preferred Investment Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained
by the Company for that purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof
from time to time. The Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of
this Preferred Investment Option, the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an
effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for
resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may
require, as a condition of allowing such transfer, that the Holder or transferee of this Preferred Investment Option, as the case may
be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Preferred
Investment Option and, upon any exercise hereof, will acquire the Preferred Investment Option Shares issuable upon such exercise, for
its own account and not with a view to or for distributing or reselling such Preferred Investment Option Shares or any part thereof in
violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to
any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on
a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
herein, in no event shall the Company be required to net cash settle an exercise of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock
certificate relating to the Preferred Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender
and cancellation of such Preferred Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred
Investment Option or stock certificate of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or
stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of
any purchase rights under this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment
Option shall constitute full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option
Shares upon the exercise of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action
as may be necessary to assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Preferred Investment Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred
Investment Option will, upon exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred
Investment Option Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred
Investment Option, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment
Option Shares upon the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment
Option is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment
Option shall be determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred
Investment Option, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by
state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Preferred Investment Option or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision
of this Preferred Investment Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those
of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred
Investment Option to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder,
shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether
such liability is asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option
and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder
from time to time of this Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent
of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder
of such provisions or the remaining provisions of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Electronic Signatures</U>. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of
the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the formula
set forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred Investment
Option Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Preferred Investment Option, execute this form and supply required information. Do not use this form to exercise
the Preferred Investment Option to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Preferred Investment Option and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: __________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: ___________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT PREFERRED INVESTMENT OPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Investment Option Shares: ______</FONT></TD><TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Issue Date: January 10, 2025</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT PREFERRED INVESTMENT OPTION (the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received,
_____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise
and the conditions hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to 5:00 p.m. (New York City time) on January 10, 2027 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter,
to subscribe for and purchase from Microbot Medical Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares
(as subject to adjustment hereunder, the &ldquo;<U>Preferred Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2(b).
This Preferred Investment Option is being issued pursuant to that certain Engagement Agreement between the Company and H.C. Wainwright
&amp; Co., LLC, dated as of May 29, 2024, as amended on January 3, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated January 7, 2025, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Preferred Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be
made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Preferred Investment Option Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified
in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. The Company shall have no obligation to inquire with respect
to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor the authority of the person so executing
such Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Preferred Investment Option to the Company until the Holder has purchased all of the Preferred Investment Option Shares available hereunder
and the Preferred Investment Option has been exercised in full, in which case, the Holder shall surrender this Preferred Investment Option
to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Preferred Investment Option resulting in purchases of a portion of the total number of Preferred Investment
Option Shares available hereunder shall have the effect of lowering the outstanding number of Preferred Investment Option Shares purchasable
hereunder in an amount equal to the applicable number of Preferred Investment Option Shares purchased. The Holder and the Company shall
maintain records showing the number of Preferred Investment Option Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Preferred Investment Option, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Preferred Investment Option Shares hereunder, the number of Preferred Investment Option Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$2.8375</B>, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment
Option may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall
be entitled to receive a number of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
    Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
    and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined
    in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder,
    either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of
    the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of
    the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading
    hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of
    &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable
    Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
    pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Preferred Investment Option, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Preferred Investment Option Shares that would be issuable upon exercise of this Preferred Investment Option in accordance
    with the terms of this Preferred Investment Option if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the <FONT STYLE="background-color: white">Purchasers
</FONT>of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment
Options being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding
period of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery of Preferred Investment Option Shares Upon Exercise</U>.
The Company shall cause the Preferred Investment Option Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder
by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its
Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either
(A) there is an effective registration statement permitting the issuance of the Preferred Investment Option Shares to or resale of the
Preferred Investment Option Shares by the Holder or (B) the Preferred Investment Option Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Preferred Investment Options), and
otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee,
for the number of Preferred Investment Option Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company
of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company
of the Notice of Exercise (such date, the &ldquo;<U>Preferred Investment Option Share Delivery Date</U>&rdquo;). Upon delivery of the
Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Preferred Investment
Option Shares with respect to which this Preferred Investment Option has been exercised, irrespective of the date of delivery of the
Preferred Investment Option Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Preferred Investment Option
Shares subject to a Notice of Exercise by the Preferred Investment Option Share Delivery Date, the Company shall pay to the Holder, in
cash, as liquidated damages and not as a penalty, for each $1,000 of Preferred Investment Option Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the third Trading Day after the Preferred Investment Option Share Delivery Date) for each Trading Day after such Preferred Investment
Option Share Delivery Date until such Preferred Investment Option Shares are delivered or Holder rescinds such exercise. The Company
agrees to maintain a transfer agent that is a participant in the FAST program so long as this Preferred Investment Option remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part,
the Company shall, at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery
of the Preferred Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder
to purchase the unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred Investment
Option shall in all other respects be identical with this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares pursuant to Section 2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind
such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other
rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option
Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Preferred Investment Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then
the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including reasonable
and customary brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Preferred Investment Option Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Preferred Investment Option and equivalent number of Preferred Investment Option Shares for
which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares
of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For
example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an
attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause
(A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the
amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver shares of Common Stock upon exercise of the Preferred Investment Option as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Preferred Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any
issue or transfer tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which
taxes and expenses shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder
or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment
Option Shares are to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Preferred Investment Option, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder
shall not have the right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
(such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Preferred Investment
Option with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, nonexercised portion of this Preferred Investment Option beneficially owned by the Holder
or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or
exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that
the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in
this Section 2(e) applies, the determination of whether this Preferred Investment Option is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Preferred Investment Option is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Preferred Investment Option, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%] [9.99%] of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Preferred Investment Option.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Preferred Investment Option held by the Holder and
the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately
adjusted such that the aggregate Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Preferred
Investment Option is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Preferred
Investment Option (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make
any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise, other than cash (including, without limitation, any distribution of stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Preferred Investment Option, then, in each such case, the Holder shall be entitled to participate
in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than solely
for the purpose of changing the Company&rsquo;s name and/or the jurisdiction of incorporation of the Company or a holding company for
the Company), (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of more than 50% of the outstanding Common Stock or more than 50% of the voting power of the common equity of the Company, (iv) the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Preferred Investment Option, the Holder shall have the right to receive, for each Preferred
Investment Option Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option), the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Preferred Investment Option is exercisable immediately prior to such
Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Preferred Investment Option from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of
this Preferred Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental
Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall
only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid to the holders
of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock
or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or
paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of
the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the volatility for the remaining exercise period as obtained from the HVT function on Bloomberg (determined utilizing
a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the share price on the day of completion of the transaction (D)
a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other
consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
&ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Preferred Investment Option
and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and
substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Preferred Investment Option a security of the Successor
Entity evidenced by a written instrument substantially similar in form and substance to this Preferred Investment Option which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Preferred Investment Option (without regard to any limitations on the exercise
of this Preferred Investment Option) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price
hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such
Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price
being for the purpose of protecting the economic value of this Preferred Investment Option immediately prior to the consummation of such
Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental
Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Preferred Investment Option (so that from
and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Preferred Investment Option
and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the
Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume
all of the obligations of the Company prior thereto under this Preferred Investment Option and the other Transaction Documents with the
same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Preferred Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. The <FONT STYLE="background-color: white">Holder agrees to maintain any information
disclosed pursuant to this <U>Section 3(f)(ii)</U> in confidence until such information is publicly available, and shall comply with
applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Preferred Investment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Preferred Investment Option and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Preferred Investment Option
at the principal office of the Company or its designated agent, together with a written assignment of this Preferred Investment Option
substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer
taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Preferred Investment Option or Preferred Investment Options in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Preferred Investment
Option evidencing the portion of this Preferred Investment Option not so assigned, and this Preferred Investment Option shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Preferred
Investment Option to the Company unless the Holder has assigned this Preferred Investment Option in full, in which case, the Holder shall
surrender this Preferred Investment Option to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment
form to the Company assigning this Preferred Investment Option in full. The Preferred Investment Option, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Preferred Investment Option Shares without having a new Preferred Investment
Option issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Preferred Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment
Options upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Preferred Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred
Investment Option or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to
be divided or combined in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated
the Issue Date of this Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number
of Preferred Investment Option Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Preferred Investment Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained
by the Company for that purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof
from time to time. The Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of
this Preferred Investment Option, the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an
effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for
resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may
require, as a condition of allowing such transfer, that the Holder or transferee of this Preferred Investment Option, as the case may
be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Preferred
Investment Option and, upon any exercise hereof, will acquire the Preferred Investment Option Shares issuable upon such exercise, for
its own account and not with a view to or for distributing or reselling such Preferred Investment Option Shares or any part thereof in
violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to
any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on
a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
herein, in no event shall the Company be required to net cash settle an exercise of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock
certificate relating to the Preferred Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender
and cancellation of such Preferred Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred
Investment Option or stock certificate of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or
stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of
any purchase rights under this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment
Option shall constitute full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option
Shares upon the exercise of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action
as may be necessary to assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Preferred Investment Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred
Investment Option will, upon exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred
Investment Option Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred
Investment Option, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment
Option Shares upon the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment
Option is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment
Option shall be determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred
Investment Option, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by
state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Preferred Investment Option or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision
of this Preferred Investment Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those
of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered to the address of the Holder in the Warrant Register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred
Investment Option to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder,
shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether
such liability is asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option
and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder
from time to time of this Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent
of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder
of such provisions or the remaining provisions of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Electronic Signatures</U>. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of
the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the formula
set forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred Investment
Option Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Preferred Investment Option, execute this form and supply required information. Do not use this form to exercise
the Preferred Investment Option to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Preferred Investment Option and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: __________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    Financial Center</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston,
    MA 02111</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">617-542-6000</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">617-542-2241
    fax</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.mintz.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
10, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">288
Grove Street, Suite 388</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braintree,
MA 02184</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Microbot Medical Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the preparation
and filing with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) of a Prospectus Supplement, dated January
7, 2025, to a Prospectus, dated December 4, 2023 (the &ldquo;<U>Prospectus and Prospectus Supplement</U>&rdquo;), filed pursuant to a
Registration Statement on Form S-3, Registration No. 333-275634 (the &ldquo;<U>Registration Statement</U>&rdquo;) and filed by the Company
with the Commission under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;). The Prospectus Supplement
relates to the sale of 3,788,550 shares (the &ldquo;<U>Securities</U>&rdquo;) of the Company&rsquo;s common stock, $0.01 par value per
share, pursuant to a Securities Purchase Agreement, dated January 7, 2025, between the Company and the purchasers named therein (the
&ldquo;<U>Purchase Agreement</U>&rdquo;). The Purchase Agreement will be filed as an exhibit to a Current Report on Form 8-K and incorporated
by reference into the Registration Statement. This opinion is being rendered in connection with the filing of the Prospectus Supplement
with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in
the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this opinion, we have (i) examined and relied upon: (A) the Registration Statement, the Prospectus and the Prospectus
Supplement, (B) the Company&rsquo;s Restated Certificate of Incorporation and Amended and Restated Bylaws, as currently in effect, and
(C) the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as
in our judgment are necessary or appropriate to enable us to render the opinion expressed below; and (ii) assumed that the Securities
to be sold by the Company will be sold at a price and on terms established by the Board of Directors of the Company or a duly constituted
pricing committee thereof in accordance with Section 153 of the Delaware General Corporation Law. As to certain factual matters, we have
relied upon a certificate of an officer of the Company and have not independently verified such matters. In rendering this opinion, we
have assumed the genuineness and authenticity of all signatures on signed documents; the authenticity of all documents submitted to us
as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of
certificates of public officials; and the due authorization, execution and delivery of all documents where due authorization, execution
and delivery are a prerequisite to the effectiveness thereof (except we have not made such assumption with respect to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinion is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any
other jurisdiction. No opinion is expressed herein with respect to the qualification of the Securities under the securities or blue sky
laws of any state or any foreign jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the foregoing, and in reliance thereon, we are of the opinion that the Securities, when sold and issued in accordance with
the Registration Statement, the Prospectus and the Prospectus Supplement, will be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K in accordance with the requirements of Item
601(b)(5) of Regulation S-K under the Securities Act and to the use of this Firm&rsquo;s name therein and in the Prospectus Supplement
under the caption &ldquo;Legal Matters.&rdquo; In giving such consent, we do not hereby admit that we are in the category of persons
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mintz,
    Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of January 7, 2025, between Microbot Medical Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities
Act (as defined below) as to the Shares and the Pre-Funded Warrants and (ii) an exemption from the registration requirements of Section
5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder as to the Preferred Investment Options, the
Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1<SUP>st</SUP>)
Trading Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located at One Financial Center, Boston, MA
02111.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities
upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agent in connection with
the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided
that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations)
or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a
majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period in Section 4.11(a) herein, and provided that any such issuance shall only be to a Person (or
to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $2.27 (less $0.0001 for each Pre-Funded Warrant), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Options</U>&rdquo; means the Series H Preferred Investment Options delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Preferred Investment Options shall be exercisable immediately upon issuance and have a term of exercise
equal to two (2) years after the initial exercise date, in the form of <U>Exhibit A-2</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Option Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Preferred Investment Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in
full, in the form of <U>Exhibit A-1</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the
Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-275634 which registers the sale of the Shares
and Pre-Funded Warrants to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the
Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare Trust Company, with offices located at Meidinger Tower, 462 South 4th Street, Louisville, KY 40202,
and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Preferred Investment Options and the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $8,600,008.50 of Shares and Warrants. Notwithstanding
anything herein to the contrary, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s Subscription
Amount (together with such Purchaser&rsquo;s Affiliates and any Person acting as a group together with such Purchaser or any of such
Purchaser&rsquo;s Affiliates) would cause such Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed the Beneficial
Ownership Limitation, or as such Purchaser may otherwise choose, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of
the Shares as determined pursuant to Section 2.2(a). The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at
the election of the Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of the Securities on the Closing Date. In each case, the election to receive Pre-Funded Warrants is solely at the option
of the Purchaser. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall
be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee. The Company shall deliver to
each Purchaser its respective Shares, Pre-Funded Warrants and Preferred Investment Option as determined pursuant to Section 2.2(a), and
the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of
the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing
documentation. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by
the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement
Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at
the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any
additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement
Shares at the Closing, and the Company shall be deemed unconditionally bound to sell such Pre-Settlement Shares to such Person at the
Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s
receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and
agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement
Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock
by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Unless otherwise directed by
the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e.,
on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer
Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent
shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent
(or its clearing firm) by wire transfer to the Company). Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as
defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered
at any time after the time of execution of this Agreement, the Company agrees to deliver the Pre-Funded Warrant Shares subject to such
notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined
in the Pre-Funded Warrants) for purposes thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
subject to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a Preferred Investment Option registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to
200% of the sum of such Purchaser&rsquo;s Shares and Pre-Funded Warrant Shares, with an exercise price equal to $2.10, subject to adjustment
therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an
expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to
such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
if applicable, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal
to the difference between (A) such Purchaser&rsquo;s Subscription Amount divided by the Per Pre-Funded Warrant Purchase Price and (B)
the number of Shares otherwise issuable to such Purchaser that would cause such Purchaser&rsquo;s Beneficial Ownership to be more than
the Beneficial Ownership Limitation with an exercise price equal to $0.0001 per share of Common Stock, subject to adjustment therein;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the
Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby makes the following
representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s)
to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required
thereby, and (iv) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities
laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the
maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the
Registration Statement in conformity with the requirements of the Securities Act, which became effective on December 4, 2023, including
the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration
Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement
or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been
instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations
of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and
any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments
thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or
supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the
Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was at
the time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities
Act and it meets the transaction requirements with respect to the aggregate market value of securities being sold pursuant to this offering
and during the twelve (12) months prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. Except for exercise of outstanding warrants and preferred investment options in the ordinary course, the capitalization
of the Company as of the date set forth therein is as set forth in the SEC Reports. The Company has not issued any capital stock since
its most recently filed periodic report under the Exchange Act, other than (i) as disclosed in a subsequent Current Report on Form 8-K,
(ii) pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, (iii) the issuance of shares of
Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans, (iv) pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act and (v) pursuant
to the exercise of outstanding warrants or preferred investment options. No Person has any right of first refusal, preemptive right,
right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as
a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the
capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is
or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance
and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any
Person (other than the Purchasers). Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the
Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument
upon an issuance of securities by the Company or any Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued
in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Except as set forth in the SEC Reports, since the date of the
latest audited financial statements included within the SEC Reports, (i) there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in the SEC Reports (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) except as set forth in the SEC
Reports, would have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any
current director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the
Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. To the Company&rsquo;s knowledge, the Company and the Subsidiaries have, or have rights to use, all patents,
patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses
and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses
as described in the SEC Reports and which the failure to so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual
Property Rights</U>&rdquo;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any
of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement, except as would not be reasonably expected to have a Material Adverse Effect or
as disclosed in the SEC Reports. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial
statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property
Rights violate or infringe upon the rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse
Effect or as disclosed in the SEC Reports. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and
there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except
where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has been advised that it will not
be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions with Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 and in which the officer,
director or employee has a direct or indirect material interest other than for (i) payment of salary or consulting fees for services
rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option
agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with
any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any
and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of
the Closing Date. Except as set forth in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and
to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. Except as set forth in the SEC Reports, the Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. Other than as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to terminate, or which to its knowledge is likely to have the effect of terminating, the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the Company is, and has
no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby is true and correct
in all material respects as of the date made and does not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the
Preferred Investment Options or Preferred Investment Option Shares under the Securities Act, or (ii) any applicable shareholder approval
provisions of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Except as disclosed in the SEC Reports, based on the consolidated financial condition of the Company as of the Closing
Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable
value of the Company&rsquo;s assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing
debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute
unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking
into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive,
were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts
on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its
ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of
the date set forth therein all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company
or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for
borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business),
(y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or
should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable
instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease
payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary
is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage
in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the
periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities
(if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging
activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any
of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any
Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company
and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last three (3) years
were, in compliance with all applicable state, federal and foreign data privacy and security laws and regulations, including, without
limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice
of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and
(iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its
subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy
Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph,
social security number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally
identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR;
and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy
Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any
court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no
registration under the Securities Act is required for the offer and sale of the Preferred Investment Options or the Preferred Investment
Option Shares by the Company to the Purchasers as contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>No General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Preferred
Investment Options or Preferred Investment Option Shares by any form of general solicitation or general advertising. The Company has
offered the Preferred Investment Options and Preferred Investment Option Shares for sale only to the Purchasers and certain other &ldquo;accredited
investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>No Disqualification Events</U>. With respect to the Preferred Investment Options and Preferred Investment Option Shares to be offered
and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, and to the Company&rsquo;s knowledge any of
its predecessors, affiliated issuer, director, executive officer, other officer of the Company participating in the offering hereunder,
beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities, calculated on the basis of voting power,
nor promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of
sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described
in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is
subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e),
and has furnished to the Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>Other Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<U>Notice of Disqualification Events</U>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing
Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time,
reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business. Such Purchaser understands that the Preferred Investment Options and the Preferred Investment Option
Shares are &ldquo;restricted securities&rdquo; and have not been registered under the Securities Act or any applicable state securities
law and is acquiring such Securities as principal for his, her or its own account and not with a view to or for distributing or reselling
such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention
of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or
indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation
of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&rsquo;s right
to sell such Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state securities
laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants, it will be either (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as
defined in Rule 144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the
Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>General Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Removal of Legends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Preferred Investment Options and Preferred Investment Option Shares may only be disposed of in compliance with state and federal
securities laws. In connection with any transfer of Preferred Investment Options or Preferred Investment Option Shares other than pursuant
to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as
contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected
by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Preferred Investment Options under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Preferred Investment Options
or Preferred Investment Option Shares in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL
INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY
SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Preferred Investment Options or Preferred Investment Option Shares to
a financial institution that is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) under the Securities Act and, if required
under the terms of such arrangement, such Purchaser may transfer pledged or secured Preferred Investment Options or Preferred Investment
Option Shares to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal
opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall
be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation
as a pledgee or secured party of Preferred Investment Options and Preferred Investment Option Shares may reasonably request in connection
with a pledge or transfer of the Preferred Investment Options or Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Certificates evidencing the Preferred Investment Option Shares shall not contain any legend (including the legend set forth in Section
4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii)
following any sale of such Preferred Investment Option Shares pursuant to Rule 144 (assuming cashless exercise of the Preferred Investment
Options), or (iii) if such Preferred Investment Option Shares are eligible for sale under Rule 144 (assuming cashless exercise of the
Preferred Investment Options), or (iv) if such legend is not required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder,
or if requested by a Purchaser, respectively. If all or any portion of a Preferred Investment Option is exercised at a time when there
is an effective registration statement to cover the resale of the Preferred Investment Option Shares, or if such Preferred Investment
Option Shares may be sold under Rule 144 (assuming cashless exercise of the Preferred Investment Options) or if such legend is not otherwise
required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff
of the Commission) then such Preferred Investment Option Shares shall be issued free of all legends. The Company agrees that following
such time as such legend is no longer required under this Section 4.1(c), the Company will, no later than the earlier of (i) one (1)
Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by
a Purchaser to the Company or the Transfer Agent of a certificate representing Preferred Investment Option Shares, as applicable, issued
with a restrictive legend (such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser
a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on
its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Preferred
Investment Option Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting
the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Preferred
Investment Option Shares issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
In addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Preferred Investment Option Shares (based on the VWAP of the Common Stock on the date
such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10
per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after the Legend Removal Date) for each Trading Day after the
Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause
to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such
Purchaser that is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an
open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion
of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of
shares of Common Stock, that such Purchaser anticipated receiving from the Company without any restrictive legend, then an amount equal
to the excess of such Purchaser&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any)
for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In
Price</U>&rdquo;) over the product of (A) such number of Preferred Investment Option Shares that the Company was required to deliver
to such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during
the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Preferred Investment Option Shares
(as the case may be) and ending on the date of such delivery and payment under this Section 4.1(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares shall be issued free of legends. If all or any portion of a Pre-Funded
Warrant is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Pre-Funded Warrant
Shares or if the Pre-Funded Warrant is exercised via cashless exercise, the Pre-Funded Warrant Shares issued pursuant to any such exercise
shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration
statement registering the sale or resale of the Pre-Funded Warrant Shares) is not effective or is not otherwise available for the sale
or resale of the Pre-Funded Warrant Shares, the Company shall immediately notify the holders of the Pre-Funded Warrants in writing that
such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is
effective again and available for the sale or resale of the Pre-Funded Warrant Shares (it being understood and agreed that the foregoing
shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Pre-Funded Warrant Shares in compliance with
applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including the Registration
Statement) registering the issuance or resale of the Pre-Funded Warrant Shares effective during the term of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the
Preferred Investment Option Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in compliance
with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason
to satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i)
or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public
Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser,
in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Preferred
Investment Option Shares, an amount in cash equal to two percent (2.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s Preferred
Investment Options on the day of a Public Information Failure and on every thirtieth (30<SUP>th</SUP>) day (pro rated for periods totaling
less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such
public information is no longer required for the Purchasers to transfer the Preferred Investment Option Shares pursuant to Rule 144.
The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b) are referred to herein as &ldquo;<U>Public Information
Failure Payments</U>.&rdquo; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month
during which such Public Information Failure Payments are incurred and (ii) the third (3<SUP>rd</SUP>) Business Day after the event or
failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure
Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for
partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public Information
Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Preferred Investment Options or Preferred Investment Option Shares
or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market
such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained
before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents, as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the
Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral,
between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, on the
one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect.
The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the
transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any
such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior
consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed,
except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice
of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior
written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction
Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the
Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with
such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and general
corporate purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment
of trade payables in the ordinary course of the Company&rsquo;s business and prior practices); or (b) for the redemption of any Common
Stock or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity, or
any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such
Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct)
or (c) in connection with any registration statement of the Company providing for the resale by the Purchasers of the Preferred Investment
Option Shares issued and issuable upon exercise of the Preferred Investment Options, the Company will indemnify each Purchaser Party,
to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i) any untrue or alleged
untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment
or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto,
in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such
untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by
such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the
Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to
any Purchaser Party under this Agreement (1) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred, provided that the Indemnified Party executes an undertaking to reimburse amounts paid if indemnification is unavailable
hereunder. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party
against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all
of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such
Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will
then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of
the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take
all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects
with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees
to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing
corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing
corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)
file any registration statement or any amendment or supplement thereto, in each case other than (v) filing a registration statement to
register the shares of Common Stock underlying the Preferred Investment Options, (x) the Prospectus Supplement, (y) filing a registration
statement on Form S-8 in connection with any employee benefit plan or (z) any supplement or amendment (or Post-Effective Amendment) to
any registration statement filed with the SEC prior to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until one (1) year following the Closing Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price; <U>provided</U>, <U>however</U>, that, after the expiration of the restrictive
period set forth in Section 4.11(a) above, the entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo;
offering with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to
obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect
damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed
to its legal and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the
contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be
restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws
from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent,
including, without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Form D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Preferred Investment Options and Preferred
Investment Option Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company
shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the
Preferred Investment Options and Preferred Investment Option Shares for, sale to the Purchasers at the Closing under applicable securities
or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of
any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<U>Registration Statement</U>. As soon as practicable (and in any event within 30 calendar days of the date of this Agreement), the Company
shall file a registration statement on Form S-1 (or other appropriate form if the Company is not then Form S-1 eligible) providing for
the resale by the Purchasers of the Preferred Investment Option Shares issued and issuable upon exercise of the Preferred Investment
Options. The Company shall use commercially reasonable efforts to cause such registration statement to become effective within 60 calendar
days following the date of this Agreement (or within 90 calendar days following the date of this Agreement in case of &ldquo;full review&rdquo;
of such registration statement by the Commission) and to keep such registration statement effective at all times until no Purchaser owns
any Preferred Investment Options or Preferred Investment Option Shares issuable upon exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
<U>Waiver of Restrictions on Subsequent Equity Sales</U>. Solely for the purpose of the issuance and sale of the Securities and the consummation
of the transactions contemplated hereby, each Purchaser signatory to that certain Securities Purchase Agreement, dated as of January
6, 2025, by and between the Company and each purchaser signatory thereto (the &ldquo;<U>January SPA</U>&rdquo;), solely and not jointly,
hereby waives the restrictions of the Company from issuing (or agreeing to issue) Common Stock and Common Stock Equivalents, as set forth
in Section 4.11(a) of the January SPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded
Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case
of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification
or waiver disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted
Purchaser (or at least 50.1% in interest of such multiple Purchasers) shall also be required. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any
subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party
to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties, and
covenants of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement. This
Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the
benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section
5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file or by any other electronic means, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; or
electronic signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company
has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because
it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in
this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy to (which shall not constitute notice):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">MBOT</FONT> SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: _________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrants: _______________ Beneficial Ownership Blocker &#9744;  4.99% or &#9744;  9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
H Preferred Investment Options: _____________ Beneficial Ownership Blocker &#9744;  4.99% or &#9744;  9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HINGHAM,
Mass., January 8, 2025 (GLOBE NEWSWIRE) &mdash; Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive
agreements for the purchase and sale of 3,788,550 shares of the Company&rsquo;s common stock at a purchase price of $2.27 per share of
common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement,
the Company will issue unregistered short-term series H preferred investment options. The short-term series H preferred investment options
to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following
issuance for a period of two years thereafter. The closing of the registered direct offering and the concurrent private placement is
expected to occur on or about January 9, 2025, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
gross proceeds to the Company from the offerings are expected to be approximately $</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6
million<FONT STYLE="background-color: white">, before deducting the placement agent&rsquo;s fees and other offering expenses payable
by the Company. The Company intends to use the net proceeds from the offerings for </FONT>the continued development, commercialization
and regulatory activities for the Company&rsquo;s LIBERTY<SUP>&reg;</SUP> Robotic System, expansion and development of additional applications
derived from the Company&rsquo;s existing IP portfolio, and for working capital and other general corporate purposes<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock described above (but not the short-term series H preferred investment options issued in the concurrent private
placement or the shares of common stock underlying such short-term series H preferred investment options) are being offered by the Company
pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-275634) previously filed with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) and declared effective by the SEC on December 4, 2023. The offering of the shares of common stock
is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final
prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies
of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC&rsquo;s website at http://www.sec.gov
or by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail
at placements@hcwco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
short-term series H preferred investment options described above are being issued in a concurrent private placement under Section 4(a)(2)
of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Regulation D promulgated thereunder and, along with
the shares of common stock underlying the short-term series H preferred investment options, have not been registered under the Securities
Act, or applicable state securities laws. Accordingly, the short-term series H preferred investment options and underlying shares of
common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable
exemption from the registration requirements of the Securities Act and such applicable state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
Microbot Medical</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions
of patients and providers globally. The Company has developed the world&rsquo;s first single-use, fully disposable endovascular robotic
system, which aims to eliminate traditional barriers to accessing advanced robotic systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Further
information about Microbot Medical is available at <U>http://www.microbotmedical.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safe
Harbor</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements
that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects&rdquo;
and &ldquo;estimates&rdquo;) should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, the completion of the offerings, the satisfaction of customary closing conditions related
to the offerings, the intended use of proceeds from the offerings, the Company&rsquo;s need for and ability to obtain additional working
capital to continue its transition to a commercially focused company, <FONT STYLE="background-color: white">market conditions, risks
inherent in the development and/or commercialization of</FONT> the <FONT STYLE="background-color: white">LIBERTY</FONT><SUP>&reg;</SUP>
Endovascular Robotic Surgical System<FONT STYLE="background-color: white">, uncertainty in the results of regulatory pathways and regulatory
approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY<SUP>&reg;</SUP> Endovascular Robotic
Surgical System in the United States, </FONT>disruptions resulting from new and ongoing hostilities between Israel and the Palestinians
and other neighboring countries, <FONT STYLE="background-color: white">need and ability to obtain future capital, and maintenance of
intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading &ldquo;Risk Factors&rdquo;
in Microbot Medical&rsquo;s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC&rsquo;s
web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required
by law</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">IR@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !K %4# 2(  A$! Q$!_\0
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M0TEK;X?_ +8?A,^(]<FM+9C9V7QB\"A='\< X,@+^(M"'AWQ<6SDO=ZZ2Q4
M  _";_@FS^QUJO[=?[9_P+_9UM6^Q>&/%?BR#5_BKK<A^S67A#X0>$+7_A)?
MB9XOU356?_B4(GA32-6(;Y0LC+O;&W/]'?Q^_:I\,_\ !<3X,?\ !3/]ECP9
MH6F6VJ?L6^(1^U)_P30\-Z?;:=8WO_#-WP'T+2/A#\5_ASI"L2H/B/X=:5X>
M^*2^'QG_ (JG6-;&3M4+^=?[*L9_X)\_\$=?VCOVT[YFT'X_?\%#M:U']B3]
ME]S$+#Q%H?P(T9?[8_:0^)VE,;%6-AXD"_\ "KUUU7)+DB/&\*?RT_X)X_M>
M>(_V%_VR/@1^T_X;CDOH?AMXVTZ7Q7H"G'_"4_#C6&_L?XA>#CPV1XA\*:MJ
M^G  J<LIS@%2 ?#U?U1_\&FW["DO[47_  433X]^*M$-_P##']CGPV/B5++<
M(?L-W\7O$;'1OA1I3\-RNWQ#XP 8*N?#"C@$,/S"_P""R'[(.A?L=_MT?$30
M?AM)%??L\?'#1]._::_9DU^R(.EZ[\"?C8'\2^'?['R -GAUSJ_@]NF?^$;!
M(!-?Z/O_  ;4_L)#]B?_ ()@_"B3Q+HTMA\6OVDW7]H?XCRW-H8+W3AXQTNS
M7X>>'LE6!'AWX<+X?+@'*^*=8\5Y #   _(S_@]T_P"3:_V%_P#LN7Q0_P#4
M#T6O\X^O]&[_ (/>/^3:?V%?^RY?%#_U!-'K_.1H [7POTO?I9_^BI**/"_2
M]^EG_P"BI** (?&W_(V^+_\ L9_$/_IV-<A77^-O^1M\7_\ 8S^(?_3L:Y"@
M#_<I_P""=?\ R81^Q3_V:9^SM_ZJ[PW7P?\ \%X_^":>J_\ !3S]A?4O@QX$
MCTB+XU^"_B'\/O'OP;U75Y-MAINL/X@M/#?C;[8^0/[&;X=^(/$).%+!M+08
M/)/WA_P3K_Y,(_8I_P"S3/V=O_57>&Z^SZ /\<[_ (+E_'GX>^,/VI?"/[(W
MP!OA-^S)_P $X/A5IW['WPAC@N<Z9KWBGP&H_P"%V_$C;]M._6O&7Q2&JA_$
M"AO^$J3PWH+A6 Q7X<5^K?\ P64_8LU/]@?_ (*,?M)_L]BRN)O!]OXQU'X@
M_"N_NE)_M+X6_%-6\3>"F! RP\-KJS>$)"0 OB?PWKF3C@?E)0!_9G_P2R_9
MQ\'_ /!<S]D[]C3X!^.-7T4_&W_@EG^TAX9TCQFFM/<?VK\1O^">7Q4UW_A(
MCH.F@H%UMO!OQ"\.'P@FS(\(^%-G[Q7\9[:_TK=-TZPTJRM],L;:WL;.PMOL
MUK9P' M+(  *.21]T'N!ZDYK^*'_ (,SOV'7\ ?L\_&[]O+QIIKP:]\?_$7_
M  J7X57-X0<?#'P#JP/C75D5A@CQA\1O^)#R2=W@ $!BQ"_V[4 ?PZ_\'O'_
M ";3^PK_ -ER^*'_ *@FCU_G(U_HW?\ ![Q_R;3^PK_V7+XH?^H)H]?YR- '
M:^%^E[]+/_T5)11X7Z7OTL__ $5)10!_8[KO_!EM^WMK6MZKJ4/[4?[)5O#J
M&IW]T(_M/QC/D!F..OPX.[+<=<]LX&!C?\047[?O_1T7[(W_ (%?&3_YW-?Z
M7]% 'SK^RW\+]8^"/[-7[/WP9\0ZAI^I^(/A/\%OA?\ ##6=3TO_ $?2]0U#
MP+X,T;PSJ>HZ8F-V&.E,P.%((P>F*^BJ** /Y<_^"_\ _P $&/&O_!6WQ+\
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MPL;2VL+2WCL;"TB$5E96$7V."V@'1! -H3D'@ <@D@$G)7^)[_P]J_X*??\
220#]KO\ \/W\1_\ Y?T4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mbot-20250107.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamDSbP9z5Z8WekhvWBybdnanywlKR4vkSYOLQWWUc8I -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:MBOT="http://MICROBOTMEDICAL.com/20250107" elementFormDefault="qualified" targetNamespace="http://MICROBOTMEDICAL.com/20250107">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://MICROBOTMEDICAL.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mbot-20250107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mbot-20250107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mbot-20250107_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mbot-20250107_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://MICROBOTMEDICAL.com/role/Cover" xlink:href="mbot-20250107.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://MICROBOTMEDICAL.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46066176661280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MICROBOT
MEDICAL INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000883975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3078125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">288
Grove Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Braintree<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-3605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBOT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MH*NVK^';@9%9\>J[D 9>I(O#-:/P$-@+X/NEE.9]8-^FRQ]#^O\!4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ I3TJ6IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "E/2I:<S.,$%\$   8$0  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ I3TJ6I^@&_"Q @  X@P   T
M             ( !H@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "E/2I:
MEXJ[',     3 @  "P              @ %^#P  7W)E;',O+G)E;'-02P$"
M% ,4    " "E/2I:JL0B%C,!   B @  #P              @ %G$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ I3TJ6B0>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ I3TJ6F60>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://MICROBOTMEDICAL.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>mbot-20250107.xsd</File>
    <File>mbot-20250107_lab.xml</File>
    <File>mbot-20250107_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "MBOT",
   "nsuri": "http://MICROBOTMEDICAL.com/20250107",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "mbot-20250107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mbot-20250107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbot-20250107_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://MICROBOTMEDICAL.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-01-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-01-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://MICROBOTMEDICAL.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001493152-25-001559-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-001559-xbrl.zip
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M.X%$Z8&$A"807#1^=(2K"DO0@.\H8-FFW)V<AS*M.YT<:5+4?WXV0(1)5CL
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M=-(RBO3C1??0?;3P"0^1 'R\B#V)':RL=>@^W*MI4N_<DX<SK> 0$Q_JJA>
MM7*$J:L.IRF(CJ'"Y^9*<9W@]D;B]<8.%4IHJ<J$TIS7[KJ@'GK$JLN14/YO
MQ%ZM>SE"N-CFD0Y^:;OP>=>1]F%-RXJD=*?"CC"K'N.&>HN5/ILM:+QBFBV2
MW#:V^C6IWAM"TI0+T&.$T.*/=O+P4*;5E0?>U?[^H*(>7->V.7VY]MG=ZU!L
M6CY4E&>UU,3#L[5)@(A-V/@,E-T?2X2.EAC?A3^_^??YL;:I*MBX>9/4:?)'
M]$)HDGGLP4<_Y^5DXR?G!BL$5)@%98@KB(VO;.=4M<U'FB!:3J>FKI&>7-HA
MV+4!4Z&$R>SNZ0<S+?\0* ,(*$9M=-\73@K[#/A1Q3CB"@VJMV SK\9*BZ4T
MB,5R"RZ:<__I>C>G^E*Z=/4-W$MANFS8G6RS_7<:/L 7&FQY09&J7:#JP4TK
M%,@9PA+7U!.CI;9$V!CQ\%P@^XAKE+"N^]^O)D-U"^)V4=Z@G_CDVZ/HO%S"
MMY]@Y5(#8@=2_;I<9O5UEJ,A^7_^'3TY.#HXBAF'%JA EKT9^HB7PIGO&9$[
MJ7LHT[)2]Z^DRM!_& [.T,;WM.(]<4I^1?QOFU$.3W<HA\]&.3S=H1QV*(>M
M5L>_M3C@)>8[$U^$*1/$1P?)3PVJ7,H]"#2-25L[WMLT3Y:UD2Y&%#8R]0_4
M02[K8;_+R'PMQ(.C)E+BPE$S\C J$(LCA_UMKLL<;-KHQB#C"5H@(-;)91A#
M#5]E^[%1C&DD3EEA,%+=(.?LE.L0\6-L9Q4V&5=7;I,;ZLW$\T43;/:&<35>
MNN=Y66)KK\OH]?[I?C2:4$@\F"TV-"<8X?<_/#X VVAM3V^X#9_\<' 4+=9]
M8X_[R<'*O[UX\7^?XZCP/_Y?M[F[O\)KUG8XN*?%Q=FVQI/408@1NX.M$1<8
M-O6TZEGIEM???@6&[V<L(+4M_0L>C^8N/=INF$C!:5:\C]YB0$KD@'I:)1;2
M65:78*C\)]%R5"'+(VN6)XX9-G# 9LO"<4'R6_!3'M0>+_^\)#)DU+31)$M%
MI!=(*DD&>;#^&DRH2SMH IR.TCVB< %KBIW *<B98%5F259)E"7"-LZ&&W'9
MIX=K4K?./A,7FH4A)47]UY*,JIQJBGJP.WE9EBF^"$Q_;1GOF [H=;93&^94
MA""ZI[B.]L-OS\< BJ0N"Y"5%9+4F$6CJ7.MN6-?A29K)!%E/L"0:TY@\AD.
MTR=A0=Y78DENP;3LE=9#V6&OM5[.CO5T10K9V5$5/.!IM05#B(7OD\IB)Q2?
M-JUP2NI3A#.ZW_G\^/RG\=G%R8O7Q\/!R0GLUW/XTQG,ZO3=V8M?QI@$> ,.
MS_CU\?;,^:_<PS5B>;\3.MH_A F\^TEJXO$@[T=OBX VZ24Y+K9K,EHN$C!W
MY-_XP;0L4FDNZW+AVO T2)9CP)PR,F#?Y!;."9)C#1IL=8$V<BZ$2FA:$ZTR
M7C;T>_RY F!P=)S@\4 @H%#^ZY_QMP<'\<'!/_>?$JJK!T6S'[TI&PS!JCF$
MH=-5<X4SY\%[\P-;N,+;3EJO8F=>(2KP "G.NJN)XXE:K98Y=<Z=5H:Y5UQ3
MW"Z0I0],%(V:\I)95KAU</]/QS-L:$L@&PT 2\]8C Q2W ^&>EF5M&#K'Z@5
M5M)LV-N:GE?M13?E,L<>O."GKAL9=W*=(J4,M9-%(FY5^FMN"FI^C.8^?>FY
M?<!P\-8^X;7'9U-6MJ[,302+R\A>O\%;9GI54H?SGB]Q@M&3JEZT3X9>DEG"
M6+E/M$I48-/[^-*08&P_NH ?N8O432KJFU,WD NV]9/][[__;_27X"0TTJTZ
ME[<H(93/>2'G.(Z^QQ]:N@VO'[9=_H[_YKL) 4R+\"67&170:76<]N7U^MRW
M7(^RJUGVP5ID1-R43G(PG:8DMPU+]WLW@P\6CH>I/4HY,^UEV(^.DUN/FN#6
M0BQ//SY.DH(VVS=9M26*=@L!>"!;".IQL#:04MG_ETQ=LHK^!1N_K*/39(4V
ML]UPTS2Y1U#@JU!$!A'Y'35Q,2Q6^B%+BA"CP!H.!RW\,_X4=GPAK A:==&+
M;F,Z@W6&_9T%G[0\"ZO?![HUL-;(<4=)0V6-F;<05M[C]0>TOBV2E^@=WELU
MG*9ZEN@9X7%,RVM3V$GVWE[N/36]"+]XM/\X#J28!]TD[T$XD%D8EG9>TBF9
MB%:IRD*;K,_XR'F_'PXTFTQ'OG,?1;=>1XB-Y ;B&***)&!B$6#\QYE(J]42
M ;QSLNKN#=ZF-H(4XE6IAW@L^$WA&'/O\A7%HLJX*[:_8J,F4((H=^=6V*EM
M35:FGN[;ZRAL-!PLID-O.+0EY-ZB,!#="3X[AX!JI4; @68U!^:K35D/'7'7
MW5TW_BZ]7\_P&0F8+!NPTBAW $OEQC-2MC:8"I@CKAVZ]+!/(X40=!6/B\+A
M1L*K)QAJ5DPZ_&-96%&GUTY Z:6A-66QKOZNZ$T7G"]7BQ,J'_?2M:_#+>Q[
MD[=7_*GL;B.A*'[Q,VT>GXHMU1T#(_+=FL$#5;.0U&Q^JRL6"228WZ#WQW!
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MYB,7,EJ[CE^E/;@9.?'/'7+BLY$3_]PA)W;(B6W3)9_@AOEWRWWY8.Z7V[;
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M%WM(/PFE%P[K%_<A$N%YA$A$#']92QK;TVP\W4Z7#6]J&T/(LJ#:/]+-8//
M\:+XV)%'?0/W\TD(+ZZNL?4Q5@$1-V)KVT*,98-LBO/D U6\W,JM;>FJ?36^
M)@2FR]$=XZ(RBZ02@0$-9E(>AB^%7*@RYT85Y/""-L3[+02O5&%%;$@EK!R4
M$S-%?G%.9!-'"<B;F1J:[),X.CHX>AR[]NMMXN/8J5L;.ZGE;WK72)M03,MQ
ME-@EC'R=W&A55I?KAE;)7X'AP%N"VAO].N9DS6C#QB[$+H&5QJB6IJ.YXDD;
M?M@G$NI#5K!_#\BW]GY>!H_&WRUKTW,9NXPZ'Z-NV9B,>6&S\'*9(OFYM&#U
M2:*\S+S';6&;>+<<_)CT5G.%L3=3]+T_$$[J0MU.P6'<I!-M\($6\J18<+DH
MS^UEZ+O"_1-$I-A/CIZ,)GO[T=AKHKU^1Z1;.0;2G$RJ#+8%/M8BI'[9X\Q1
M4*;D=>Y;__XH?+U8-)R3U@ITC2G+G]93E<A6WGZJ.6N<I=V8M7"L\+(LBZ9:
MBK&C^2D/W3)+IFQJ(QH#0=^-!K;#K[0L*OJ:A,XS<@!<XA>^0;8^#MF^MK;]
MEFB(L/N@VU'.G[GN=2'%>FM/Z>!UU$P<]%IO/45"CO8A%*-S#[%B<H/9+P]$
MWR<!][N5H-,^;B\Q,/]I.]GZ@MLF%!#6COT;IIMK*P5SC*/;4HFL D,%(\B(
MY6=5;(.<<#LAV W-[KBUW>$MB"N?-()#R.96;SGC?\/) V_M,I.B0U2[Y"><
M/WK<<6S7?;'W!AD.=#\0WV<,+X2?20HWM*^(/+F\Q(*$QF@!)AA 2V[LX;:=
M&;OJ,D^[5D2)S3KH"B;!6%9ZO30W)H=+8'1XM!>!.=)<U7ZUL/?+N%.L];.D
ML$]<2ZSH9/_Y_K?6Q\*UVR*#_U.BJH>[J.KG1U4/=U'5751UJT('EQPZ>,$N
MHX0]@])8--9MOR#$,WMU?5+9RF;-PO;AS%P?SG+!$ 6Y:4%0LP+O:(R$UF)_
M3H.7=R'.UDQ,.:REJE_-KJR^K7ZWZZ'BW6TMHU7+92:*%'!%8&+SLD83<<K%
M#>S*+F QRS2;"O.#=]G"DC%A ?FF'N2.D5Y8SS?-R<NG!"#6$I(.P8:)5$ A
M T;_E2ZN?S[Z/S'E&_=:5ZD)]@3!'^7*&"VK7/A@ZS[HAO^]:)$G"$[G6&H
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M"P.BPN0<8TK!^8+#-913+5VX NM#7"^*#MQEQ4!H$2^&OU0!Y"<0*C"F ($
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M(XMH/^$[GA.OMM>E&G3V6W2=ZU]U;^G.%3:>=B2/8) T+.O0*R(D@0>!.&!
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MWY)T?KQ+.G]^TOGQ+NF\2SIOG=D\D1((VQ,.+@(&/J/CQHC;>IWUG$P1<J1
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M[.VQE^#B)\P.@;@)ISMP@VLFNIQEZ7*:\2F1>*V#96S5K?J5N> SX>276L&
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M<?!L$)KWZ:1AA[3#I!WXH0W<!OG._E['EYSCTN3,H6MO;M1XE9&0JN;4=OJ
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M@6-$-"&CZUJC\&A^0RTHG%PC/'Q# WS8M5+DN#4K)M8WXAD$6R@-ITR@3"&
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M6.HX@CC,:5DW#XZ4P^Q0_CC0?$+/B)'0BQH,YT<O0DI)L[;OST'U80'&)[L
MX\<'&)_L HR[ ..],@4N5YL"D F&-.T2^-)#C<_0%F@')"ZQ)  )25%#U+W#
M5TTBU0I+$H(AD(#<>& ',)D((@7DGM^8OO.]; !4(;7D*1@P612Y8*_*"> %
M;LKI#5V3_W#OP#CH&8R728P^-*#QW@]9?A= \ ,RVI(<2X8_X$OQYA,!O3+,
M94+].)0)P6B276[00Y22KI#& #<W- ;&&D%<B#XB>$,E$5#1[APFGKF.6J%
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M9/,NV7S/+!M24_F505T3YZ@P2!@/Y")95>&;G!,C:P<]2Q",1C.Z6VI% K4
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MM/:-XPM,Y&(:I 2+,H[NH*=N4G*DA\&,,2'JXG-& K?-SO-**S(?JS=EOY@
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M_4M=?(I=](7EC#,^.,XNF[&9>(RJ"^&E6!>#U1(8@2/".0[@\/I+R('C2V[
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MC6HTN1KF3DA/5EN=L7EB;\'Q5?)FU].\:6Y@1?NAY]V OBMKU)DT3N@P-#1
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M#DU-"]7Q![D+EGAAGV^]L.OTPC[?>F&W7MCO1R)(P/EC5L!#8/^,2M\[1"_
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MP]2X@U_63$WXC^ET@Y8--@/U _U1&?\)FC2L, QF#N<U&)5RXF0R6+"IGI&
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MTGYLZMC$6.4]0=L)10B,3V>FTC6/GA::!3OP-T1,2%*=7IX,[ :H"O:=:B
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MJ.3!F$4=ZHJB/3Y!Z3ASTOK8ZHKDTED\33V7L,C>(165R-8FC1'CEL18A0!
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M2*\B!>5WRT0@B#U?61-.BG* )!>6;";S![%!4=@H=KL=:/$'.=3+<02/'^V
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MSKO0'S&ZBYJU2HM93A/UC!0];E8PV?NB2F:*^5$JF@X3O5'<&96(T6IEYBK
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M0B/+,E*LT&U+B9&RM-#0UER:,7?> Q!3A%-X!F@B*H1I6)!!^!@N .,J$0G
MJHA;?#:5@ ..<\,!L%X#+MKA0Q%-K Q1/X$X"6-(&8&)9YE.,RW)!X C%!]!
MZ NK^TXAG!U>/<0MV@A#F3P2<3H[M%MO2X25&U,XW>3Y2J5"@J:D?2:-5\O=
M7!?M=YC)T:=(B)HU27GI(->/8FFFBW)YG'(=D;-.)3R5I]#MY1ICC6-1@>"
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M%U\1F[FHD-X\$KLT&U-@\-;S"%TV:DW&I*FFC 8O)F7-PF<H7+35LS'6+*2
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M$X9!30 EOFPD;H9:-*]Q1S0"S-R\DKXQX4$8;I9'E F?;*[>W#$8"& P8*H
M _T!IHJ!=CUZV[XCBZE51^>^<6!G!=YX&C&NI<OKA*9/@9"+-:X>RO$P2"RP
MC!:DU8=%YS:(R3P/^2XT>5#M^-JFY"L;C!?9EB4MCX .XF%(V8&PJ:7-U R'
M.N%#1<PF[.4#?C#QBAK6+0\,D7_3X6@/ ,]GR<E)(PBJAC7N"E9'^A&F/'X&
M#>39A"%^@@DT<^QB-F4NXFD[BP-!;FA8)<)?29-M/N235PYX$!D#HL("Q*$$
M R9@0%#Q2K^[@E@C6.4HGM& MT;= 0_=LA]CL-31\<@7_I0@*XE8L@,.-$S$
M7,QB/L8,4PV3!B(4"-%?S-@H:CA*,F*=&$6Y:Q2*GX#/R:T<W#60863AXU2R
MA4(A*P7G'R7^R.<2-2C ([P./_*,;4R8%I-@=RXS>>D?:B5;JQ04OK\$=$P\
M6,V=F=BTFZZ=YA5&%D".KS,76!N!N(VHY, -5*NU;+E8G7/_1)H@YM=$^DXX
M@(N\WCGE$O-YDUZDP#)E%$58H:D.8I9[AR3=.PPM YSB 45V6^"F5DL[E:BC
M>C1V$)>0F17)1W-R(QL%&3U9W$YF2G,YREU\6F"21U+W<6H3&X7"<*J_R+:&
M@0@LP&8@Y5QC2OC'X%S?"Q6ZD$;-KSG@<+.G)7@Z',J([$#JSB))N-L!3%H4
M&\MS;'VL"62BX(E8L>*#L7#\E(DD]YI(3N1$4G(/@'=<_$1?;^P*S@9_@IL+
MMLF4KFW?Y)RQ92%R0A1 9U@D7%#H$J<"A1N^2PJWM'49C;NFH85I(V@['Q#"
MH/^/L>$!$8K?.=.P;D"XVYB*ZGI1Z3SF!AA07P*B)##AND?"\=XM,R<LQY<_
MW(@6#<K/TX*2LA8MD,FZ<+5\@Q:5L,\/7/:@I,8\'13,VX9<S@B)$Q"-3"G$
MPUJ23A3@)N#.N&K(^B3=0W6W4=DD79P=YKK<IEYD9G*!/?+\XC@7HXP.E S7
MBQ.@^PW4,IN*-"?]ELDD9D(>C*C!S4O>79PV,#+AV7ER -+W41.H/'0"B9C
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M2^1TQ<D#F(& :0#T;K@#<<A#%YX#W]+GQUM"G]4GO,#YL1EVXBGBYF6T:!"
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M;ND1,$=<8$8;AETH&@!1A[F83AK&R\"\'S3;;0/<W;Y_!]13_V":X!$CXM9
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MO1P+$2D2R]DA;'Y6_B*&4.:D(+;*Z4IN:0DM6C)5'<OVX7#^Q S?Q5E-X+"
M2KXZI1$V*<G+>=58_Q <5X@$'Q5!_R.<Z_:,+L@ZW]<"=2M24\O?4$L#!!0
M   ( *4]*EJMG%[P_@H  ("&   5    ;6)O="TR,#(U,#$P-U]L86(N>&UL
MS9U=;^.X%8;O"_0_L.Y-"XSCB=,MD.QD%QE/LC VFZ2Q9[;MHEC0$N,(H<F
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ME:"\%MOOE]<W7<M/<K/>)/]:X93(+?\%4$L#!!0    ( *4]*EJN%X;/Y@<
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MEOP  &5X-"TR+FAT;5!+ 0(4 Q0    ( *4]*EI%A;5+DPD   XV   )
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H="TR,#(U,#$P-U]P<F4N>&UL4$L%!@     )  D $P(  !"1 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbot-20250107.xsd" xlink:type="simple"/>
    <context id="AsOf2025-01-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883975</identifier>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-01-07" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-01-07" id="Fact000004">0000883975</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-01-07" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-01-07" id="Fact000010">2025-01-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-01-07" id="Fact000011">MICROBOT MEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-01-07" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-01-07" id="Fact000013">000-19871</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-01-07" id="Fact000014">94-3078125</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-01-07" id="Fact000015">288 Grove Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-01-07" id="Fact000016">Suite 388</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-01-07" id="Fact000017">Braintree</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-01-07" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-01-07" id="Fact000019">02184</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-01-07" id="Fact000020">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-01-07" id="Fact000021">875-3605</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-01-07" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-01-07" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-01-07" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-01-07" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-01-07" id="Fact000026">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-01-07" id="Fact000027">MBOT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-01-07" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-01-07" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
